Biostem Technologies, Inc. (NASDAQ:BSEM) Stock Short Interest Report for October

Biostem Technologies, Inc. (NASDAQ:BSEM) was the recipient of a significant increase in short interest during the month of October. As of October 15th, there was short interest totaling 333,843 shares, an increase of 239.1% from the September 30th total of 98,453 shares. Approximately 1.8% of the shares of the company are sold short. Based on an average daily trading volume, of 110,434 shares, the days-to-cover ratio is presently 3.0 days.

Biostem Technologies Price Performance

Shares of BSEM stock traded down $0.12 during trading hours on Friday, reaching $1.17. The company had a trading volume of 79,635 shares, compared to its average volume of 101,039. Biostem Technologies has a 12 month low of $1.20 and a 12 month high of $8.40. The business has a fifty day simple moving average of $3.13 and a 200-day simple moving average of $4.22. The company has a market cap of $21.75 million, a price-to-earnings ratio of -0.73 and a beta of 0.17.

Biostem Technologies (NASDAQ:BSEM) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.02). The firm had revenue of $7.90 million for the quarter, compared to the consensus estimate of $6.35 million. Biostem Technologies had a negative return on equity of 60.22% and a negative net margin of 76.02%. On average, equities research analysts expect that Biostem Technologies will post -1.90 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on BSEM. Weiss Ratings initiated coverage on shares of Biostem Technologies in a report on Wednesday, August 19th. They issued a “sell (d-)” rating on the stock. Wall Street Zen upgraded shares of Biostem Technologies to a “sell” rating in a research note on Saturday, September 5th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Biostem Technologies presently has an average rating of “Hold” and an average price target of $9.00.

Biostem Technologies Company Profile

BioStem Technologies, Inc is a biotechnology company focused on regenerative medicine and biologic tissue products. The company develops, manufactures and commercializes human tissue allografts intended to support wound care, tissue repair and other medical applications.

Its product portfolio includes placental- and birth-tissue-derived products, such as amniotic membrane and umbilical cord allografts. These products are marketed for use by healthcare providers in areas including wound management, surgical procedures and related regenerative-care applications.

BioStem Technologies serves the U.S.